-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Guillain-Barré syndrome (GBS) is a heterogeneous disease that causes muscle weakness, sensory changes, and autonomic dysfunction, often involving cranial neuropathy
.
Immune responses to triggers such as recent infections or vaccines are considered to be the cause of the disease
It is an autoimmune peripheral neuropathy characterized by demyelination of peripheral nerves and nerve roots and inflammatory cell infiltration of small blood vessels.
Case 2: A 43-year-old male patient with a 10-day history of muscle pain, severe neck pain, urinary retention, severe weakness on both sides, difficulty swallowing, changes in taste, and tongue paresthesia
.
I received the first dose of Vaxzevria 11 days before the onset of symptoms
Case 3: A 51-year-old male started to experience severe leg cramps and pain after receiving Vaxzevria for one week.
He has a three-week medical history
.
Three days later, his feet and hands were numb and extended to the vicinity of his ankles
Case 4: A 71-year-old woman was infected with COVID-19 5 weeks before the vaccination
.
Twelve days after vaccination, she developed low back pain and abdominal pain
Case 5: A 53-year-old man developed discomfort and pain in the lower back.
A few days after vaccination, he developed abnormal paresthesias in the face, mouth and lower limbs, and developed severe bilateral weakness at the same time
.
Upon examination, he had severe LMN bilateral lateral weakness, but his strength elsewhere was normal
A recent UK-based study found that there is no causal relationship between GBS and COVID-19 infection
.
Compared with previous years, the incidence of GBS in 2020 has decreased.
The cases have significant clinical homogeneity: the number of days between vaccination and the onset of symptoms is 7-12; the phenotypic characteristics of severe facial diplegia and paresthesia; persistently high cerebrospinal fluid protein levels
.
MRI of bilateral lateral nerves was enhanced
To date, 1 million people have died worldwide, and vaccination remains a global health priority
.
Monitoring for this potential complication is important
.
BonifacioGB ,Patel,D ,CookS BonifacioGB Bonifacio Patel,D Patel, CookS Cook , et Al -Bilateral with paraesthesia Facial Weakness of Guillain-Barré syndrome Variant following Vaxzevria COVID.
19-Vaccine Journal of.
Neurology, Neurosurgery & Psychiatry in this message
